Mycoplasma Contamination Detection in Biopharmaceuticals
Presenting impact of Mycoplasma contamination, available testing methods, and why Syngene prefers NAT-based Mycoplasma detection method over other methods.
How Syngene’s ‘first-time right’ process advanced a novel vascular calcification inhibitor API from Lab-scale to Tox-batch manufacturing successfully
Learn how Syngene supported a pharma company in developing and manufacturing lab-scale and later Tox batches of its target molecule through an improved synthesis route. All this while meeting chemical purity requirements of >98%.
Holistic Target Identification and Validation services
Syngene’s Target Identification and Validation services combine data, informatics, and knowledge about biological target assays for holistic target assessment and risk mitigation in drug discovery.
ADME/PK profiling capabilities
Syngene, with its comprehensive suite of DMPK profiling assays, can help you achieve a high rate of success with your clinical candidates across drug modalities.
Choosing the ‘right’ CRO-CDMO in Biopharma – What has changed
Learn the new criteria that have emerged as more important for selecting an outsourcing partner consequent to disruptions caused by the COVID-19 pandemic.
How Syngene is implementing Green Chemistry in pharmaceutical development – Design to Delivery
Learn how Syngene is helping pharma companies minimize environmental impact using its Green Chemistry approach to drug development.
How Syngene synthesized a complex cyclic peptide for use in novel drug therapies
Learn how Syngene’s novel approach helped synthesize a complex 11-mer cyclic peptide for use in drug therapies.
How Syngene delivered pre-IND to IND Safety studies for a leading biotech company in just three months
Learn how Syngene partnered with a biotech company to deliver pre-IND to IND Safety studies in just three months for a treatment therapy for gut-brain diseases.
Targeted Protein Modulators – Cellular to ADME to PK/PD models and correlations
Presenting the cellular translation to degradation and functional response across different assay platforms using a PROTAC tool SynTAC-ERD, an Estrogen Receptor (ER) degrader.
Five questions that determine the success of your PROTAC programs
Challenges in developing PROTACs and critical questions that need to be addressed to move PROTAC molecules from Target to IND successfully.
